OA12760A - Metabolites of (3-ÄÄ4-tert-butyl-benzyl)-(pyridine-3-sulfonyl)-aminoÜ-methylÜ-phenoxy)-acetic acid. - Google Patents

Metabolites of (3-ÄÄ4-tert-butyl-benzyl)-(pyridine-3-sulfonyl)-aminoÜ-methylÜ-phenoxy)-acetic acid. Download PDF

Info

Publication number
OA12760A
OA12760A OA1200400198A OA1200400198A OA12760A OA 12760 A OA12760 A OA 12760A OA 1200400198 A OA1200400198 A OA 1200400198A OA 1200400198 A OA1200400198 A OA 1200400198A OA 12760 A OA12760 A OA 12760A
Authority
OA
OAPI
Prior art keywords
methyl
pyridine
sulfonyl
benzyl
amino
Prior art date
Application number
OA1200400198A
Other languages
English (en)
Inventor
Kimberly O'keefe Cameron
Kim Anne Johnson
Bruce Allen Lefker
Chandra Aggarwal Prakash
Original Assignee
Pfizer Prod Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Prod Inc filed Critical Pfizer Prod Inc
Publication of OA12760A publication Critical patent/OA12760A/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4406Non condensed pyridines; Hydrogenated derivatives thereof only substituted in position 3, e.g. zimeldine
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D213/00Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/89Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members with hetero atoms directly attached to the ring nitrogen atom
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/08Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D213/00Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/62Oxygen or sulfur atoms
    • C07D213/70Sulfur atoms
    • C07D213/71Sulfur atoms to which a second hetero atom is attached

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Epidemiology (AREA)
  • Pyridine Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
OA1200400198A 2002-01-31 2003-01-20 Metabolites of (3-ÄÄ4-tert-butyl-benzyl)-(pyridine-3-sulfonyl)-aminoÜ-methylÜ-phenoxy)-acetic acid. OA12760A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US35374802P 2002-01-31 2002-01-31

Publications (1)

Publication Number Publication Date
OA12760A true OA12760A (en) 2006-07-04

Family

ID=27663249

Family Applications (1)

Application Number Title Priority Date Filing Date
OA1200400198A OA12760A (en) 2002-01-31 2003-01-20 Metabolites of (3-ÄÄ4-tert-butyl-benzyl)-(pyridine-3-sulfonyl)-aminoÜ-methylÜ-phenoxy)-acetic acid.

Country Status (29)

Country Link
US (1) US6852863B2 (xx)
EP (1) EP1470109A1 (xx)
JP (1) JP2005521668A (xx)
KR (1) KR20040077884A (xx)
CN (1) CN1625549A (xx)
AP (1) AP2004003094A0 (xx)
AR (1) AR038332A1 (xx)
BR (1) BR0307339A (xx)
CA (1) CA2473984A1 (xx)
EA (1) EA200400724A1 (xx)
EC (1) ECSP045215A (xx)
GB (1) GB2400100B (xx)
HN (1) HN2003000051A (xx)
HR (1) HRP20040683A2 (xx)
HU (1) HUP0500012A2 (xx)
IL (1) IL162167A0 (xx)
IS (1) IS7281A (xx)
MA (1) MA27169A1 (xx)
MX (1) MXPA04004960A (xx)
NO (1) NO20043569D0 (xx)
OA (1) OA12760A (xx)
PA (1) PA8564601A1 (xx)
PE (1) PE20030978A1 (xx)
PL (1) PL371982A1 (xx)
TN (1) TNSN04138A1 (xx)
TW (1) TW200302080A (xx)
UY (1) UY27632A1 (xx)
WO (1) WO2003064391A1 (xx)
ZA (1) ZA200404067B (xx)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UA67754C2 (uk) * 1997-10-10 2004-07-15 Пфайзер, Інк. Агоністи простагландину, фармацевтична композиція на їх основі (варіанти), спосіб нарощення та збереження кісткової маси у хребетних та спосіб лікування (варіанти)
US7666330B2 (en) * 2005-04-20 2010-02-23 Lg Chem, Ltd. Additive for non-aqueous electrolyte and secondary battery using the same
NZ573964A (en) * 2006-07-28 2010-11-26 Pfizer Prod Inc isopropyl [3-({[4-(1H-pyrazol-1-yl)benzyl](pyridin-3-ylsulfonyl)-amino}methyl)phenoxy]acetate, a prostaglandin E2 receptor agonist (EP2), useful in lower intraocular pressure thereby treating glaucoma
AU2008226947B2 (en) 2007-03-08 2014-07-17 The Board Of Trustees Of The Leland Stanford Junior University Mitochondrial aldehyde dehydrogenase-2 modulators and methods of use thereof
EP2002834A1 (de) * 2007-06-13 2008-12-17 Bayer Schering Pharma Aktiengesellschaft Aryl/Hetarylamide als Modulatoren des EP2-Rezeptors
PL2264009T3 (pl) 2008-03-12 2019-07-31 Ube Industries, Ltd. Związek stanowiący kwas pirydyloaminooctowy
EP2149551A1 (de) 2008-07-30 2010-02-03 Bayer Schering Pharma AG N-(Indol-3-ylalkyl)-(hetero)arylamidderivate als Modulatoren des EP2-Rezeptors
EP2149552A1 (de) 2008-07-30 2010-02-03 Bayer Schering Pharma AG 5,6 substituierte Benzamid-Derivate als Modulatoren des EP2-Rezeptors
EP2149554A1 (de) 2008-07-30 2010-02-03 Bayer Schering Pharma Aktiengesellschaft Indolylamide als Modulatoren des EP2-Rezeptors
JP2012502048A (ja) 2008-09-08 2012-01-26 ボード オブ トラスティーズ オブ ザ レランド スタンフォード ジュニア ユニバーシティ アルデヒドデヒドロゲナーゼ活性のモジュレーターおよびその使用方法
US8389522B2 (en) 2008-10-28 2013-03-05 The Board Of Trustees Of The Leland Stanford Junior University Modulators of aldehyde dehydrogenase and methods of use thereof
SI2415763T1 (sl) 2009-03-30 2016-05-31 Ube Industries, Ltd. Farmacevtski sestavek za zdravljenje ali preprečevanje glavkoma
DE102009049662A1 (de) 2009-10-13 2011-04-14 Bayer Schering Pharma Aktiengesellschaft 2,5-Disubstituierte 2H-Indazole als EP2-Rezeptor-Antagonisten
US10457659B2 (en) 2011-04-29 2019-10-29 The Board Of Trustees Of The Leland Stanford Junior University Compositions and methods for increasing proliferation of adult salivary stem cells
TW201326154A (zh) 2011-11-28 2013-07-01 拜耳知識產權公司 作為ep2受體拮抗劑之新穎2h-吲唑
JP6410790B2 (ja) 2013-03-14 2018-10-24 ザ ボード オブ トラスティーズ オブ ザ レランド スタンフォード ジュニア ユニバーシティー ミトコンドリアアルデヒドデヒドロゲナーゼ−2調節因子およびその使用方法

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UA67754C2 (uk) * 1997-10-10 2004-07-15 Пфайзер, Інк. Агоністи простагландину, фармацевтична композиція на їх основі (варіанти), спосіб нарощення та збереження кісткової маси у хребетних та спосіб лікування (варіанти)

Also Published As

Publication number Publication date
CN1625549A (zh) 2005-06-08
TNSN04138A1 (fr) 2007-03-12
JP2005521668A (ja) 2005-07-21
IS7281A (is) 2004-05-21
EA200400724A1 (ru) 2004-12-30
TW200302080A (en) 2003-08-01
PL371982A1 (en) 2005-07-11
HN2003000051A (es) 2003-09-24
IL162167A0 (en) 2005-11-20
BR0307339A (pt) 2004-12-07
ZA200404067B (en) 2005-08-29
MXPA04004960A (es) 2005-04-08
NO20043569L (no) 2004-08-26
MA27169A1 (fr) 2005-01-03
GB2400100B (en) 2006-04-12
CA2473984A1 (en) 2003-08-07
AR038332A1 (es) 2005-01-12
US20030216445A1 (en) 2003-11-20
HRP20040683A2 (en) 2004-10-31
GB0413967D0 (en) 2004-07-28
US6852863B2 (en) 2005-02-08
AP2004003094A0 (en) 2004-09-30
GB2400100A (en) 2004-10-06
PE20030978A1 (es) 2003-11-19
UY27632A1 (es) 2003-08-29
ECSP045215A (es) 2004-09-28
EP1470109A1 (en) 2004-10-27
KR20040077884A (ko) 2004-09-07
WO2003064391A1 (en) 2003-08-07
HUP0500012A2 (hu) 2005-04-28
PA8564601A1 (es) 2003-09-05
NO20043569D0 (no) 2004-08-26

Similar Documents

Publication Publication Date Title
OA12760A (en) Metabolites of (3-ÄÄ4-tert-butyl-benzyl)-(pyridine-3-sulfonyl)-aminoÜ-methylÜ-phenoxy)-acetic acid.
JP6022657B2 (ja) キナーゼカスケードを調節するための組成物および方法
SK4752000A3 (en) Prostaglandin agonists and their use to treat bone disorders
CZ223399A3 (cs) Agonisté prostaglandinu
KR20050071472A (ko) 퀴놀린 항생 물질 중간체의 제조 방법
WO2001057044A1 (fr) Derives de pyrido-oxazine
JP3480835B2 (ja) 2−(3,5−ビス−トリフルオロメチル−フェニル)−N−メチル−N−(6−モルホリン−4−イル−4−o−トリル−ピリジン−3−イル)−イソブチルアミド
EP2158201A2 (fr) Derives de 7 -alkynyl-1.8-naphthyrid0nes, leur preparation et leur application en therapeutique
WO2004007495A1 (ja) ピロロピリジン誘導体およびその用途
WO2007080324A2 (fr) Derives de pyrido-pyrimidone, leur preparation, leur application en therapeutique.
US20010041725A1 (en) Novel urea derivatives having nitrogen aromatic heterocycle
EP0003277B1 (en) Heterocycle substituted (3-loweralkylamino-2-ro-propoxy)pyridines, process for preparing the same,and pharmaceutical composition containing the same
EP2729447B1 (en) Positive allosteric modulators of nicotinic acetylcholine receptor
IE911913A1 (en) Benzoic acid derivatives for treating leukotriene-related¹diseases
JPS59118784A (ja) 置換イミダゾ〔1,5−a〕ピリジン及びその製造方法,並びに該化合物を含有する医薬
AU2003239465A1 (en) Metabolites of (3-{[4-tert-butyl-benzyl)-(pyridine-3-sulfonyl)-amino]-methyl}-phenoxy)-acetic acid
WO2020148325A1 (en) Neutral lxr modulators
EP3891155B1 (en) 6-hydroxy-8-oxatricyclo[3.2.1.02,4]octane-2-carboxamide derivatives for inducing chondrogenesis for treating joint damage
EP2185516A2 (en) Polymorphs of 3-(((4-tert-butyl-benzyl)-(pyridine-3-sulfonyl)-amino)-methyl)-phenoxy)-acetic acid sodium salt or a hydrate thereof and methods for making the same
EP0532634A1 (en) Phthalamic acids and their isomers for treating leukotriene-related diseases
EP0532621A1 (en) Amide linked pyridyle-benzoic acid derivatives for treating leukotriene-related diseases
WO2009027803A2 (en) Polymorphs of (3-(((4-tert-butyl-benzyl)-(pyridine-3-sulfonyl)-amino)-methyl)- phenoxy)-acetic acid, free acid
US20110046385A1 (en) Polymorphs Of Prostaglandin Agonists And Methods For Making The Same
CZ20001280A3 (cs) Agonisté prostaglandinu a jejich použití pro léčení chorob kostí
MXPA00003478A (en) Prostaglandin agonists and their use to treat bone disorders